Obesity is now very common among patients with Crohns disease, yet there is limited guidance on how newer metabolic medications, particularly GLP-1 receptor agonists affect Crohns-related outcomes, presenting author Nakul Ganju, MD, an internal medicine resident at Howard University Hospital in Washington, DC, told GI & Hepatology News
Reduced Inflammation : Both peptides have anti-inflammatory properties
It is approved in Japan under the brand name GHRP Kaken 100 for that diagnostic use
Of course, the composition of the present invention can be supplied in a pre-filled syringe for self-administration
Over time, factors like age, stress, and diet can reduce GLP-1 activity, making it harder to manage cravings, energy, and weight